ONCOSIL MEDICAL ORD
OncoSil Medical Secures TGA Approval in Australia for Pancreatic Cancer Device
OncoSil Medical wins TGA approval for OncoSil device to treat unresectable LAPC; ARTG-listed, enabling Australian launch as manufacturing scales up.
Weekly wrap: six days of gains as rate cuts outlook improves
Expectations of central bank interest rate cuts drove global markets higher, carrying the Australian market up for its sixth straight day of gains. Stronger than expected US retail spending prompted a solid day on Wall Street after retail sales data topped expectations and jobless applications were lower than expected. That strength carried over on to […]
OncoSil Medical sees 78% surge in brachytherapy device use for pancreatic cancer
OncoSil Medical (ASX: OSL) has announced a 78% increase in the number of doses of its OncoSil single-use brachytherapy device used in commercial treatments for patients with pancreatic cancer, reflecting a growing adoption of the device in clinical practice. The increase was recorded during the three months to the end of June and was 2.7 […]
OncoSil Medical obtains CE Mark and breakthrough device designation for its pancreatic tumour isotope
Medical device company OncoSil Medical (ASX: OSL) has announced that it has finally received the CE Mark from the British Standards Institute (BSI) for its proprietary OncoSil device – a means of treating locally advanced pancreatic cancer (LAPC) in combination with chemotherapy. The company said OncoSil is a first in class medical device comprising microparticles containing phosphorus-32, […]
